Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
Barbara Ma, Niroshana Anandasabapathy
Journal of Investigative Dermatology (2021) Vol. 142, Iss. 3, pp. 951-959
Open Access | Times Cited: 17

Showing 17 citing articles:

Immune-related adverse events of immune checkpoint inhibitors: a review
Qinan Yin, Liuyun Wu, Lizhu Han, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 128
Current status of skin cancers with a focus on immunology and immunotherapy
Mahsa Khayyati Kohnehshahri, Aila Sarkesh, Leila Mohamed Khosroshahi, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 35
Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations
Kristian C. Williams, Abigail Gault, Amy E. Anderson, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
William Shipman, Katelyn Singh, Jeffrey M. Cohen, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 3, pp. 339-341
Open Access | Times Cited: 14
Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report
Luping Zhao, Zhen Cheng, Li Piaopiao
Frontiers in Oncology (2025) Vol. 14
Open Access
Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade
Zelin Li, Shuhan Liu, Deyu Liu, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Dermatologic toxicities related to cancer immunotherapy
Yosra Vaez-Gharamaleki, Mohammad Amin Akbarzadeh, Farhad Jadidi‐Niaragh, et al.
Toxicology Reports (2025), pp. 102021-102021
Open Access
Autoimmune-related adverse events induced by immune checkpoint inhibitors
Yini Sun, Ziyang Zhang, Jia Ke, et al.
Current Opinion in Immunology (2025) Vol. 94, pp. 102556-102556
Closed Access
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
Taku Fujimura, Yusuke Muto, Yoshihide Asano
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15720-15720
Open Access | Times Cited: 17
Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
Ting Cao, Xuyang Zhou, Xingbiao Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Cutaneous lupus erythematosus induced by tislelizumab
Weiquan Chen, Xuan Song, Ying Zhou
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 7, pp. 1003-1004
Closed Access | Times Cited: 1
Loss of epidermal Langerhans cells in psoriasiform lesions of de novo induced or worsened pre‐existing psoriasis following uses of immune checkpoint inhibitors
Misaki Kase, Yasuyuki Fujita, Asako Ota, et al.
The Journal of Dermatology (2022) Vol. 49, Iss. 9, pp. 916-920
Closed Access | Times Cited: 5
Molecular Docking and Intracellular Translocation of Extracellular Vesicles for Efficient Drug Delivery
Yasunari Matsuzaka, Ryu Yashiro
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 12971-12971
Open Access | Times Cited: 5
Kutaner Lupus erythematodes ausgelöst durch Tislelizumab
Weiquan Chen, Xuan Song, Ying Zhou
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 7, pp. 1003-1005
Closed Access
Immune-related dermatological adverse events of antitumor immunotherapy with PD-1, PD-L1, CTLA-4 inhibitors
Anastasiya Yu. Syryseva, Е. А. Шатохина, Aleksandra S. Polonskaia, et al.
Russian Journal of Skin and Venereal Diseases (2024) Vol. 27, Iss. 2, pp. 121-133
Closed Access
Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022
Clara Furrer-Matcau, Chloé Sieber, Dirk Lehnick, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review
Ranferi Ocaña‐Guzmán, Diego Osorio-Pérez, Leslie Chávez‐Galán
Pharmaceuticals (2023) Vol. 16, Iss. 8, pp. 1119-1119
Open Access | Times Cited: 1
Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management
John M. Pach, Jonathan S. Leventhal
Critical Reviews in Immunology (2022) Vol. 42, Iss. 4, pp. 1-20
Closed Access | Times Cited: 2
Autoimmune Skin Diseases and Immune Checkpoint Inhibitors
Davide Fattore, Luca Potestio, Lucia Genco, et al.
Critical Reviews in Immunology (2022) Vol. 42, Iss. 3, pp. 11-22
Closed Access | Times Cited: 1
Page 1

Scroll to top